Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated